AIM AIM ImmunoTech Inc.

MIXED Impact: 5/10 424B5
Horizon days Filed May 19, 2026 Processed 24d 17h ago SEC 0001493152-26-024458
Notable filing: 424B5
Latest settled — T+5d ⚠ clustered
AIM ▲ +60.00% at T+5d
NEUTRAL call ✓ call won +60.00% · α vs SPY +58.76% · entry $0.2500 → $0.4000
Next anchor: T+20d in 4d
Currently $0.4100 · +64.00% from $0.2500 entry
Entry anchored
May 19, 04:15 PM ET
via Databento tick
T+1d
-4.00%
call -4.00% · α -4.19%
$0.2400
settled 24d ago
T+5d
+60.00%
call +60.00% · α +58.76%
$0.4000
settled 17d ago
T+20d
call — · α —
in 4d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

AIM ImmunoTech filed a 424B5 to suspend its equity distribution agreement (ATM) with Maxim Group, halting further sales under the current shelf. The suspension removes near-term dilution overhang, but the company has already sold $2.85M of the $3.41M registered, and a simultaneous 8-K revealed a Q1 EPS miss (-$0.57 vs -$0.37) and ongoing financial distress for this $3M market cap micro-cap.

Actionable Insight

The suspension is a temporary positive as it removes immediate ATM overhang, but the company still needs capital and faces deep operating losses. Monitor for any new financing announcements or further dilution restructuring. The stock is highly volatile and fundamentals remain weak.

Key Facts

  • Suspends sales under the Equity Distribution Agreement; no further ATM sales until a new prospectus supplement is filed.
  • As of May 19, 2026, $2,847,151.09 of common stock had been sold under the EDA (out of $3,409,174 registered).
  • Stock price was $0.4080 per share on May 18, 2026.
  • 8-K filed same day reports debt extension with Streeterville to June 2027, improved equity ($2.1M vs -$9.8M deficit), and Q1 EPS miss.
  • Market cap is approximately $3M, indicating extreme micro-cap risk.

Financial Impact

Removes potential future dilution of up to ~$562k (remaining registered amount). Already sold $2.85M, which is substantial relative to market cap.

dilution

Risk Factors

  • Further capital needs may force dilutive financing at low prices.
  • Debt with Streeterville (amended again) suggests ongoing liquidity pressure.
  • Low cash runway and negative earnings per share persist.

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (5 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001493152-26-024458
Document: 0001493152-26-024458-index-headers.html0001493152-26-024458
Document: 0001493152-26-024458-index.html0001493152-26-024458
Document: 0001493152-26-024458.txt0001493152-26-024458
19 reports for AIM
Performance horizon
56% Hit rate 5 of 9 directional calls best @ T+20▲ +46.55%Apr 13, 2026
Filters
Rows
Reports for AIM — sortable, filterable
Type Now
Jun 11, 2026
1d ago
8-K
BEARISH ★ 7/10
$0.4543 awaiting T+1awaiting T+1$0.4100 (+9.75%)
Jun 10, 2026
2d ago
424B5
BEARISH ★ 7/10
$0.4477 awaiting T+1awaiting T+1$0.4100 (+8.42%)
Jun 8, 2026
5d ago
Press Release
BULLISH ★ 5/10
$0.4589 awaiting T+1awaiting T+1$0.4100 (−10.66%)
Jun 4, 2026
9d ago
8-K
NEUTRAL ★ 3/10
$0.5900 $0.5200▼ −11.86%▼ −9.27%$0.4100 (−30.51%)
Jun 1, 2026
12d ago
Press Release
NEUTRAL ★ 4/10
$0.9000 $0.8300▼ −7.78%▼ −7.92%$0.4100 (−54.44%)
May 21, 2026
22d ago
8-K
BEARISH ★ 8/10
$0.2400 $0.2400· 0.00%▲ +0.45%$0.4100 (−70.83%)
May 21, 2026
22d ago
424B5
BEARISH ★ 7/10
$0.2400 $0.2400· 0.00%▲ +0.45%$0.4100 (−70.83%)
May 20, 2026
23d ago
Press Release
BEARISH ★ 7/10
$0.2500 $0.2400▲ +4.00%▲ +4.19%$0.4100 (−64.00%)
May 19, 2026
24d ago
424B5
MIXED ★ 5/10
$0.2500 $0.2400▼ −4.00%▼ −4.19%$0.4100 (+64.00%)
May 19, 2026
25d ago
8-K
MIXED ★ 6/10
$0.4100 $0.2500▼ −39.02%▼ −40.06%$0.4100 (−0.00%)
Showing 10 of 19

US Market Status

Market Closed — Opens Mon (47h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access